Clinical trial
Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes…
NCT00346242 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00346242 |
|---|---|
| Title | Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events |
| Official title | Evaluation of Efficacy of Zoledronic Acid in Patients With Haemoglobin Syndromes (Thalassemia and Sicle Cell Anaemia) and Risk of Skeletal Events |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Thalassemia |
| Intervention type | Drug |
| Interventions | Zoledronic Acid |
| Enrollment | 60 |
| Start date | Mar 1, 2004 |
| Primary completion | Mar 1, 2006 |
| First posted | Jun 29, 2006 |
| Last update posted | May 1, 2012 |
| Countries | Greece |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: